Trastuzumab Triggers Phagocytic Killing of High HER2 Cancer Cells In Vitro and In Vivo by Interaction with Fcγ Receptors on Macrophages

Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation

(2014) Yun Shi et al.   BREAST CANCER RESEARCH

Experimental Antibody Therapy of Liver Metastases Reveals Functional Redundancy between Fc RI and Fc RIV

(2014) M. A. Otten et al.   JOURNAL OF IMMUNOLOGY

Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients

(2013) Branka Petricevic et al.   Journal of Translational Medicine

Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function

(2012) Y.-T. Tai et al.   BLOOD

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer

(2012) Holbrook E. Kohrt et al.   JOURNAL OF CLINICAL INVESTIGATION

Tumor-Associated Macrophages Promote Invasion while Retaining Fc-Dependent Anti-Tumor Function

(2012) K. D. Grugan et al.   JOURNAL OF IMMUNOLOGY

High numbers of tumor-associated macrophages correlate with poor prognosis in patients with mature T- and natural killer cell lymphomas

(2012) Ze-Xiao Lin et al.   MEDICAL ONCOLOGY

Monocyte Subsets Responsible for Immunoglobulin G-Dependent Effector Functions In Vivo

(2011) Markus Biburger et al.   IMMUNITY

Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study

(2011) Ningyan Zhang et al.   mAbs

Therapeutic Antibodies to Human L1CAM: Functional Characterization and Application in a Mouse Model for Ovarian Carcinoma

(2010) S. Wolterink et al.   CANCER RESEARCH

Fc RIV deletion reveals its central role for IgG2a and IgG2b activity in vivo

(2010) F. Nimmerjahn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Trastuzumab-Induced HER Reprogramming in "Resistant" Breast Carcinoma Cells

(2009) M. Narayan et al.   CANCER RESEARCH

M2 Macrophages Phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro

(2009) M. Leidi et al.   JOURNAL OF IMMUNOLOGY

Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage Fc RI, Fc RIII, and Fc RIV

(2008) V. Minard-Colin et al.   BLOOD

Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40

(2008) E Oflazoglu et al.   BRITISH JOURNAL OF CANCER

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

(2008) Antonino Musolino et al.   JOURNAL OF CLINICAL ONCOLOGY

Correlation between NK function and response to trastuzumab in metastatic breast cancer patients

(2008) Alessandra Beano et al.   Journal of Translational Medicine

Optimization of antibody binding to Fc RIIa enhances macrophage phagocytosis of tumor cells

(2008) J. O. Richards et al.   MOLECULAR CANCER THERAPEUTICS

Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling

(2008) Qing-Bai She et al.   PLoS One